Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study

William Trattler, Kamran Hosseini, William Trattler, Kamran Hosseini

Abstract

Introduction: Bromfenac is a well-known topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) that is commercialized in the USA and other regions of the world. A new formulation, 0.075% bromfenac in DuraSite®, was developed to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery. We hypothesized that efficacy and safety would be enhanced with twice-daily (BID) dosing compared to once-daily (QD) dosing.

Methods: This was a multicenter, double-masked, comparative study in which 40 and 45 subjects were randomized to groups receiving BID dosing and QD dosing, respectively. Subjects self-instilled the study drug for 14 days postoperative and were followed for an additional 2-week evaluation phase. The primary efficacy endpoint was the proportion of subjects with an anterior chamber cell (ACC) grade of 0 at day 15.

Results: A total of 45 subjects had cleared ACC (grade "0") at day 15, of whom 21 were in the BID group (52.5%) and 24 were in the QD group (53.5%). A secondary analysis found 7/40 (17.5%) subjects in the BID group and 10/45 (22.2%) subjects in the QD group achieved an ACC grade of 0 at day 8. There were more adverse events in the QD group (n = 16) than in the BID group (n = 12).

Conclusion: Similar outcomes were observed for subjects using Bromfenac 0.075% in DuraSite® in the BID and QD dosing regimens for the treatment of post-cataract surgery inflammation.

Trial registration: ClinicalTrials.gov identifier, NCT01190878.

Funding: InSite Vision (now a division of Sun Pharma).

Keywords: Bromfenac; Cataract surgery; Cyclooxygenase inhibitor; DuraSite®; Nonsteroidal anti-inflammatory drugs.

References

    1. Cho H, Wolf KJ, Wolf EJ. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199–210. doi: 10.2147/OPTH.S4806.
    1. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22(6):1133–1140. doi: 10.1185/030079906X112471.
    1. Donnenfeld ED, Donnenfeld A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin. 2006;46(4):21–40. doi: 10.1097/01.iio.0000212134.83513.11.
    1. Henderson BA, Gayton JL, Chandler SP, et al. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology. 2011;118(11):2120–2127. doi: 10.1016/j.ophtha.2011.04.035.
    1. Silverstein SM, Cable MG, Sadri E, et al. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin. 2011;27(9):1693–1703. doi: 10.1185/03007995.2011.597663.
    1. Senju Pharmaceutical Co. Bronuck (package insert). Senju Pharmaceutical Co., Osaka, 2009.
    1. ISTA Pharmaceuticals. Xibrom (package insert). ISTA Pharmaceuticals, Irvine, 2010.
    1. ISTA Pharmaceuticals. Bromday (package insert). ISTA Pharmaceuticals, Irvine, 2011.
    1. Committee for Medicinal Products for Human Use (CHMP). Yellox Assessment Report. Report No.: EMA/431843/2011. European Medicines Agency, London, 2011.
    1. Bowman LM, Si E, Pang J, et al. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther. 2009;25(2):133–139. doi: 10.1089/jop.2008.0066.
    1. InSite Vision. BromSite (prescribing information). InSite Vision, Alameda, 2016.
    1. Hosseini K, Hutcheson J, Bowman LM. Aqueous humor concentration of Bromfenac 0.09% (Bromday) compared with Bromfenac in DuraSite 0.075% (Bromsite) in cataract patients undergoing phacoemulsification after 3 days dosing. Association for Research in Vision and Ophthalmology. Seattle, 2013.
    1. Luchs J. Azithromycin in DuraSite for the treatment of blepharitis. Clin Ophthalmol. 2010;4:681–688. doi: 10.2147/OPTH.S6370.
    1. Malhotra R, Gira J, Berdy GJ, Brusatti R. Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery results of a prospective parallel-group investigator-masked study. Clin Ophthalmol. 2012;6:855–863. doi: 10.2147/OPTH.S29604.
    1. Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(8):3425–3429. doi: 10.1167/iovs.06-1413.
    1. Shafiee A, Bowman LM, Hou E, Hosseini K. Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clin Ophthalmol. 2013;7:1549–5156. doi: 10.2147/OPTH.S48766.
    1. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. doi: 10.2147/OPTH.S31902.
    1. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59(Suppl):S93–S96. doi: 10.4103/0301-4738.73693.
    1. Tsai T, Robin AL, Smith JP., III An evaluation of how glaucoma patients use topical medications: a pilot study. Trans Am Ophthalmol Soc. 2007;105:29–33.
    1. Comte L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34(4):549–558. doi: 10.1007/s10928-007-9058-0.
    1. Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi: 10.1111/j.1525-1470.2009.00981.x.
    1. Tsai T, Kroehl M, Smith S, et al. Efficacy and safety of twice- versus once-daily dosing of lisinopril for the treatment of hypertension. In: 50th Midyear meeting of the American Society of Health-System Pharmacists. New Orleans, LA, 2015.
    1. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103–111. doi: 10.1111/j.1538-7836.2004.01100.x.
    1. Lan AJ, Colford JM, Colford JM., Jr The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. Pediatrics. 2000;105(2):E19. doi: 10.1542/peds.105.2.e19.
    1. Zeng C, Wei J, Li H, et al. Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep. 2015;5:10593. doi: 10.1038/srep10593.
    1. de la Pena A, Ma X, Reddy S, et al. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014;8(4):821–829. doi: 10.1177/1932296814532326.
    1. Wielders LH, Lambermont VA, Schouten JS, et al. Prevention of cystoid macular edema after cataract surgery in nondiabetic and diabetic patients: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(5):968–981e33. doi: 10.1016/j.ajo.2015.07.032.
    1. Elsawy MF, Badawi N, Khairy HA. Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery. Clin Ophthalmol. 2013;7:1245–1249. doi: 10.2147/OPTH.S39188.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner